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Abstract: Colorectal cancer is one of the main causes of cancer-related mortality in the developed
world. Carcinogenesis is a multistage process conventionally defined by the initiation, promotion
and progression stages. Natural polyphenolic compounds can act as highly effective antioxidant and
chemo-preventive agents able to interfere at the three stages of cancer. Cocoa has been demonstrated
to counteract oxidative stress and to have a potential capacity to interact with multiple carcinogenic
pathways involved in inflammation, proliferation and apoptosis of initiated and malignant cells.
Therefore, restriction of oxidative stress and/or prevention or delayed progression of cancer stages
by cocoa antioxidant compounds has gained interest as an effective approach in colorectal cancer
prevention. In this review, we look over different in vitro and in vivo studies that have identified
potential targets and mechanisms whereby cocoa and their flavonoids could interfere with colonic
cancer. In addition, evidence from human studies is also illustrated.
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1. Introduction
Cancer is a multistage process conventionally defined by three stages: initiation, promotion and
progression [1]. Development of colon cancer typically is initiated from normal epithelial cells via
aberrant crypts and progressive adenoma stages to carcinomas in situ and then metastasis. Along
this process, oxidative stress has the potential to affect numerous signaling pathways related to the
proliferation of initiated cells and enhanced malignant transformation [2]. In the initiation stage, the
generation of reactive oxygen species (ROS) has been involved in DNA damage and in the development
of aberrant crypt foci (ACF) [3,4], the earliest identifiable precancerous lesions in colon cancer [5].
Similarly, in the post-initiation/promotion stages, ROS also contribute to abnormal gene expression
and modification of second-messenger systems in epithelial cells within the ACF. In this manner,
several signaling pathways involved in cell survival are deregulated, resulting in an increase in cell
proliferation and/or a decrease in the apoptosis of the initiated cell population [5]. Therefore, inhibition
of oxidative stress together with the modulation of signaling routes related to cell survival/proliferation
exerted by natural antioxidant compounds seems to be an effective approach in preventing and
slowing down the initiation and progression of colon cancer. In fact, the identification of natural
bioactive compounds that downregulate cell proliferation or upregulate apoptotic processes could
be a complementary and useful strategy to control the development and progression of colon cancer,
and it has become an essential subject for study in current research [6,7]. In this regard, cocoa and
its flavonoids have shown other anticarcinogenic properties independently of their conventional
antioxidant activity [7–10]. Consequently, cocoa polyphenols could be considered as promising
candidates for colon cancer chemoprevention.
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Cocoa, the dried and either unfermented or fermented seeds derived from Theobroma cacao, has
the highest flavanol content of all foodstuffs on a weight basis and is a significant contributor to the
total dietary intake of flavonoids [11–13]. In fact, for many individuals, cocoa products constitute a
larger proportion of the diet than foodstuffs containing bioactive compounds with similar properties,
such as green tea, wine or soy beans [14].
However, health effects derived from cocoa flavonoids depend on their bioavailability, which is
also affected by their chemical structure [15]. In this regard, fermented cocoa contains high quantities of
flavanols (´)-epicatechin (EC), (´)-catechin and their dimers procyanidins B2 (PB2) and B1 (Figure 1),
although other polyphenols, such as naringenin, luteolin, apigenin, quercetin, isoquercitrin (quercetin
3-O-glucoside), quercetin 3-O-arabinose and hyperoside (quercetin 3-O-galactoside), have also been
found in minor amounts [16]. Interestingly, in comparison to other flavonoid-containing foodstuffs,
cocoa and its derivative products exhibit a high concentration of larger procyanidins that are poorly
absorbed through the gut barrier, and consequently, their beneficial effects would be restricted to
the gastrointestinal tract, where they may have an important antioxidant and anticarcinogenic local
function [6–10]. Thus, those oligomers and polymers of flavanols that are not absorbed in the intestine
could be metabolized by the microbiota into low molecular weight phenolic acids, which are more
bioavailable, and might be well absorbed through the colon [17,18]. Additionally, recent findings have
demonstrated that some of the microbial metabolites derived from cocoa consumption also retain
biological properties [19].
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Figure 1. Main flavonoids present in fermented cocoa. Chemical structures of (−)-epicatechin and  
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Evidence for chemoprevention by bioactive substances is achieved from a combination of 
epidemiological, animal and basic mechanistic studies. Consequently, the interest for understanding 
the mode of action of cocoa and its flavanols has been recently rising, especially in cultured colonic 
cells, although it has not been fully elucidated. In addition, it also remains to be demonstrated 
whether these mechanisms are involved in cancer prevention in humans. In the present work, 
different in vitro studies that have identified the potential targets and mechanisms whereby cocoa 
and their polyphenolic compounds could interfere with colonic cancer cells are reviewed. Then, the 
potential beneficial effects of cocoa in animal models of colon cancer are summarized, and finally, 
some evidence from human studies is also provided. 
2. Chemopreventive Effects in Cultured Cells 
The effect of cocoa and its main flavanols against colon cancer have been studied in cultured 
cells, which also allow the elucidation of their molecular mechanisms of action (Table 1). All of these 
studies have shown that pathways responsible for the potential chemopreventive activity of cocoa 
and its flavonoids are mainly related to their antioxidant and anti-inflammatory properties and their 
ability to inhibit proliferation and to induce apoptotic cell death. In addition, to the best of our 
knowledge, it should be noted that no studies have been performed in HT-29 cells, which is one of 
the “standard” colon cancer cell models. 
Figure 1. Main flavonoids present in fer ented cocoa. Chemical structures of (´)-epicatechin and
(´)-catechin and their respective dimmers, procyanidins B2 and B1.
Evidence for chemoprevention by bioactive substances is achieved from a combination of
epidemiological, animal and b sic mechanistic studies. Consequently, the int r st f r understanding
the mode of action of cocoa and its flavanols has been recently rising, especially in cultured colonic
cells, although it has not been fully elucidated. In addition, it also remains to be demonstrated
whether these mechanisms are involve in cancer prevention in humans. In the present work, different
in vitro studies that have identified the potential targets and mechanisms whereby cocoa and their
polyphenolic compounds could interfere with colonic cancer cells are reviewed. Then, the potential
beneficial effects of coco in animal models f colon ancer are summarized, and finally, some evidence
from human studies is also provided.
2. Chemopreve tive Effects in Cultured Cells
The effect of cocoa and its main flavanols against colon cancer have been studied in cultured cells,
which also allow the elucidation of their molecular mechanisms of action (Table 1). All of these studies
have shown that pathways responsible for the potential chemopreventive activity of cocoa and its
flavonoids are mainly related to their antioxidant and anti-inflammatory properties and their ability to
inhibit proliferation and to induce apoptotic cell death. In addition, to the best of our knowledge, it
should be noted that no studies have been performed in HT-29 cells, which is one of the “standard”
colon cancer cell models.
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Table 1. Effects of cocoa and cocoa flavonoids on colonic cancer cultured cell lines a. The arrow indicates an increase (Ò) or decrease (Ó) in the levels or activity of the
different analyzed parameters, and “=” designates an unmodified parameter. DOC, deoxycholic acid.
Biological Activity Flavonoid Cell Concentration Output References
Antioxidant Cocoa Caco-2 10 µg/mL acrylamide-incubated cells: Ó GSH depletion,Ó ROS generation, Ò γ-GCS, Ò GST [20]
Antioxidant Procyanidin B2 Caco-2 10 µM (5.79 µg/mL) acrylamide-incubated cells: ÓGSH depletion,Ó ROS generation, Ò γ-GCS, Ò GST [20]
Antioxidant Epicatechin Caco-2 10 µM (2.9 µg/mL) acrylamide-incubated cells: Ó GSH depletion,Ó ROS generation [20]
Apoptosis and
proliferation/survival Cocoa Caco-2 10 µg/mL Ó acrylamide-induced caspase-3 and p-JNK [20]
Apoptosis and
proliferation/survival Procyanidin B2 Caco-2 10 µM (5.79 µg/mL)
Ò ERK, Ò p38, Ó acrylamide-induced
caspase-3 and p-JNK [20]
Antioxidant Catechin Int-407 100 µM (29 µg/mL) Ó lipid peroxidation, Ó ROS formation, ÒGPx, Ò GR, Ò Nrf2, Ò HO-1 [21]
Antioxidant Epicatechin Caco-2 1–10 µM(0.29–2.9 µg/mL)
t-BOOH-treated cells: Ó ROS generation, Ó
LDH, = GPx, = GST, = GR [22]
Apoptosis and
proliferation/survival Procyanidin B2 Caco-2 10 µM (5.79 µg/mL) Ó t-BOOH-induced caspase-3 [22]
Apoptosis and
proliferation/survival Epicatechin Caco-2 10 µM (2.9 µg/mL) Ó t-BOOH-induced caspase-3 [22]










procyanidins Caco-2 10 µM (2.91 µg/mL) Ó DOC-induced AKT, ERK, p38 and AP-1 [24]
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Table 1. Cont.
Biological Activity Flavonoid Cell Concentration Output References
Antioxidant Hexamer procyanidins Caco-2 2.5–20 µM(0.73–5.81 µg/mL)
t-BOOH-treated cells: Ó ROS
generation, Ó LDH Ó DOC-induced
cytotoxicity, Ó oxidant generation, Ó
NADPH oxidase, Ó Ca2+
[24,25]
Anti-inflammatory Hexamer procyanidins Caco-2 2.5–60 µM(0.73–17.4 µg/mL)
TNF-treated cells: Ó NF-κB
activation (Ó p-IkB, Ò IkB, Ó p50 and







Ó PGE2, Ò COX-1, IL-stimulated
cells: Ó PGE2, = IL-8, = NF-κB [26]
Anti-inflammatory Cocoa Caco-2 10 µg/mL TNF-treated cells: Ó IL-8, Ó COX-2,Ó iNOS, Ó NFκB activation [27]
Cell cycle Polymer procyanidins Caco-2 5–100 µg/mL





Cell cycle Epicatechin LoVo 5–1000 µM(1.45–290 µg/mL) S arrest [29]
Apoptosis and
proliferation/survival Procyanidin B2 SW480
10–50 µM
(5.79–28.93 µg/mL) Ò proliferation, Ò p-AKT, Ò p-ERK [30]
Apoptosis and
proliferation/survival Procyanidin B2 Caco-2
10–50 µM
(5.79–28.93 µg/mL) = proliferation, = p-AKT, = p-ERK [30]
Apoptosis and
proliferation/survival Epicatechin SW480 and Caco-2
10–50 µM
(2.9–14.5 µg/mL) = proliferation, = p-AKT, = p-ERK [30]
a Concentration in µg/mL was calculated as epicatechin equivalents.
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2.1. Antioxidative Effects
Aerobic organisms cannot avoid free radical and ROS generation, which are produced during
normal oxygen metabolism or induced by exogenous damage [9,31]. In a physiological situation,
cells maintain the balance between the generation and counteraction of ROS through non-enzymatic
processes (mainly glutathione (GSH)) and enzymatic defenses (catalase (CAT), glutathione peroxidase
(GPx), glutathione reductase (GR), glutathione-S-transferase (GST) superoxide dismutase (SOD),
etc.) [9,31]. However, when the cellular balance is altered and antioxidant defenses overwhelmed,
cells can be damaged. Thus, ROS overproduction may lead to the formation of highly reactive
oxidation products, activation of carcinogens, formation of oxidized DNA bases and DNA strand
breaks. All of these modifications might provoke errors during DNA replication and genetic alterations,
modulate transcription of redox-regulated proteins, etc., leading to enhanced cell proliferation and
tumor promotion/progression [31].
Cocoa and its flavonoids are strong antioxidant substances. Cocoa retains a potent antioxidant
capacity as compared to other foods, such as teas and red wine, and this property has been associated
to its flavonoid content [11]. Remarkably, the structural characteristics of flavanols allow them to act as
hydrogen donors (radical-scavenging) and metal-chelating antioxidants. In addition, cocoa and its
flavonoids can prevent the DNA damage caused by free radicals or carcinogenic agents acting through
the modulation of enzymes related to oxidative stress (CAT, GR, GPx, SOD, etc.) and the alteration of
the procarcinogenic metabolism by inhibiting phase I drug-metabolizing enzymes (cytochrome P450)
or activating phase II conjugating-enzymes (glucuronidation, sulfation, acetylation, methylation and
conjugation) [6]. In this regard, colonic cancer Caco-2 cells pretreated for 20 h with a cocoa phenolic
extract or with the pure cocoa flavanols EC and PB2 at realistic concentrations (10 µg/mL for cocoa
phenolic extract and 10 µM for EC and PB2, respectively) prevented acrylamide-induced cytotoxicity
(5 mM for 24 h) by restraining GSH consumption and ROS generation [20]. In detail, the reduced GSH
content and the subsequent enhanced ROS generation induced by the toxic were highly prevented
by the cocoa extract and PB2, whereas these effects were only partially restored by EC incubation.
This feature could be partially attributed to the fact that the monomer mainly acted as a free radical
scavenger. Nevertheless, similar to what was reported for other polyphenols and antioxidants [6],
PB2 and the cocoa phenolic extract could protect cells by counteracting several types of radicals,
upregulating antioxidant defenses and modulating signaling pathways related to cell survival. In this
line, PB2 and the cocoa phenolic extract were able to augment the levels of gamma-glutamyl cysteine
synthase (γ-GCS) and glutathione-S-transferase (GST) in the mentioned experimental conditions in
Caco-2 cells [20].
Cocoa and its phenolic compounds also exert their protective effect towards oxidative stress by
targeting the transcription factor NF-E2-related factor-2 (Nrf2) and the Kelch-like ECH-associated
protein 1 (Keap1), which participate in the regulation of the antioxidant response element (ARE).
Thus, the regulation of Keap1 can lead to the nuclear accumulation of Nrf2 and the subsequent ARE
activation [6]. Hence, catechin (100 µM) decreased lipid peroxidation and ROS and increased the
activity of GPx and GR, total sulfhydryl groups, as well as the expression of Nrf2 and hemeoxygenase-1
(HO-1) in a time-dependent manner in intestinal Int-407 cells [21].
Pure PB2 and EC (1–10 µM) reduced ROS generation without affecting GSH content in Caco-2 cells,
and PB2 evoked a dose-dependent increase in GPx, GR and GST activities after 20 h of incubation [22].
Consequently, Caco-2 cells treated with EC or PB2 (10 µM) for 20 h and then submitted to an oxidative
stress induced by tert-butyl hydroperoxide (t-BOOH, 400 µM) presented a reduced ROS production,
evoked a protection from necrosis (measured as decreased lactate dehydrogenase (LDH) leakage)
and showed higher viability than cells plainly incubated with the stressor [22]. Furthermore, this
protective effect exerted by PB2 (10 µM, for 20 h) against the oxidative injury induced by t-BOOH
occurred through the upregulation of the expression of GSTP1 [23]. PB2 treatment also enhanced
nuclear Nrf2 levels at 3 h, peaked at 6 h and remained elevated up to 20 h of incubation. Accordingly,
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this procyanidin significantly increased the GSTP1 mRNA levels and activity at 4–20 h of incubation,
which was accompanied by enhanced protein expression levels at 8 and 20 h [23].
Cocoa procyanidin dimers and trimers protected Caco-2 cells from the loss of integrity of the
bilayer induced by oxidants through the interaction with membrane phospholipids, presumably with
their polar head group [32]. In this line, a cocoa hexameric procyanidin fraction (2.5–20 µM) interacted
with the Caco-2 cell membranes preferentially at the water–lipid interface without affecting their
integrity after 30 min of incubation [24,25]. Likewise, this hexameric procyanidin fraction inhibited
the deoxycholic acid (DOC)-induced cytotoxicity and partly prevented the generation of oxidants
following NADPH oxidase inhibition, as well as the DOC-evoked increase in cellular calcium [24,25].
2.2. Anti-Inflammatory Effects
Chronic inflammation, infections and immune diseases lead to oxidative stress, which has been
linked to carcinogenesis [6]. In fact, chronic inflammation constitutes a major risk for colorectal
cancer [6,7,33], and most inflammation-associated colorectal cancers retain the activation of the
transcription factor nuclear factor-kappa B (NF-kB) and inflammatory mediators (tumor necrosis
factor (TNFα), cyclooxygenase-(COX)-2, etc.), all of these markers being related to cell proliferation,
anti-apoptotic activity, angiogenesis and metastasis [6].
Cocoa extract repressed the inflammatory mediator prostaglandin E2 (PGE2) in human cancer
Caco-2 cells [26]. Cells treated with a polyphenolic extract of cocoa (equivalent to 50 µM of gallic
acid) for 4 h and later stimulated with interleukin-(IL)-1β for 24 or 48 h displayed a reduced PGE2
synthesis, although IL-8 secretion and NF-κB activity continued to increase [26]. Unexpectedly, the
cocoa polyphenolic extract and without a pro-inflammatory stimulus induced a basal PGE2 synthesis
in Caco-2 cells after 24 h of incubation. This result has been related to the stimulation of COX-1, which
seems to be involved in preserving the mucosal integrity [26].
Furthermore, pretreatment with a cocoa phenolic extract, at a realistic dose (10 µg/mL) for 20 h,
reduced the increase in IL-8 secretion and both COX-2 and inducible nitric oxide synthase (iNOS)
expressions provoked by TNFα (40 ng/mL for 24 h) in Caco-2 cells [27]. In these experimental
conditions, cocoa phenolic extract reduced both phosphorylated levels of c-Jun N-terminal kinase
(JNK) and nuclear translocation of NK-κB induced by TNFα, pointing to the relevance of this pathway
to reduce the intestinal inflammation [27]. Similarly, Caco-2 cells treatment with 2.5–20 µM hexameric
procyanidins for 30 min, prior to incubation with TNFα (10 ng/mL) for a further 5–30 min, avoided the
TNFα-induced NF-kB activation, prevented the phosphorylation and degradation of the inhibitor of
κB (IκB), p50 and RelA nuclear translocation and NF-kB-DNA binding, as well as iNOS expression and
cell oxidant increase [25]. These effects take place because hexameric procyanidins can interact with
the plasma membrane of the intestinal cells to preferentially inhibit the binding of TNFα to its receptor
and the subsequent NF-kB activation [25]. In this regard, a very recent study on human colon cancer
cells suggests that high-molecular weight polymeric cocoa procyanidins may be the most effective
for preventing loss of gut barrier function and epithelial inflammation, which are critical steps in the
pathogenesis of inflammatory bowel disease and colon cancer [34].
2.3. Antiproliferative and Apoptotic Effects
Suppression of cell proliferation and induction of differentiation and apoptosis are relevant
strategies in preventive approaches. Deregulated cell cycle and resistance to apoptosis are hallmarks
of cancer [6,7]. Cell cycle control is a highly regulated process, and any alteration of cell cycle-specific
proteins (cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors, etc.) can alter and/or inhibit the
continuous proliferation of cancer cells [6]. Therefore, regulation of cell cycle constitutes an important
target for cocoa and its polyphenols in chemoprevention.
Procyanidin-enriched extracts and procyanidins prevented Caco-2 cell growth [28]. After 48 h
of treatment, procyanidins extracts with a flavanol and procyanidin content of 501 mg/g induced
25% growth inhibition, whereas the procyanidin-enriched extracts (flavanol and procyanidin content:
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941 mg/g) provoked a 75% growth inhibition. In contrast, cocoa powder samples, which consisted
of a flavanol and procyanidin content of 141 mg/g, did not evoke any growth inhibitory effect in
Caco-2 cells. Moreover, 50 µg/mL procyanidin-enriched extracts blocked the cell cycle at G2/M phase,
without inducing apoptosis, and reduced the polyamine metabolism by constraining the ornithine
decarboxylase and S-adenosylmethionine decarboxylase activities, which has been partly associated
with the cell cycle blockage at the G2/M phase [28]. Likewise, incubation of colon cancer-derived
LoVo cells with 5 and 1000 µM EC for 24 h arrested the cell cycle in the S phase without inducing
apoptosis [29]. Importantly, lower concentrations of EC seemed to slightly promote the proliferation of
LoVo cells.
Programmed-cell death, which may be considered one of the important targets in a preventive
approach against cancer, is a complex process that involves the active participation of affected cells in
a self-destruction cascade [6,7]. Apoptosis induction implicates the participation of death receptors
(extrinsic pathway) and/or the mitochondria (intrinsic route), leading to the modulation of pro- and
anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, Bid, Bad, Bax, etc.) [6,7]. Both cascades converge in a
common executor mechanism involving DNA endonucleases, which cleave regulatory and structural
molecules and activated proteases (caspases) and lead to the cellular death [6,7].
Cocoa polyphenols prevent the cytotoxicity evoked by oxidative stress inducers through the
ability of these compounds to restrain the increase in ROS levels and the subsequent activation of
caspase-3, which leads to apoptosis induction [7]. Consequently, incubation of Caco-2 cells with PB2
(10 µM) and a cocoa polyphenolic extract (10 µg/mL) or with EC or PB2 (10 µM) for 20 h protected
against acrylamide- and t-BOOH-induced apoptosis, respectively [20,22]. Likewise, pretreatment with
hexameric procyanidins (2.5–20 µM) delayed the deoxycholic acid-induced apoptosis in Caco-2 cells,
as repressed caspase-3 activation by halting poly-(ADP-ribose) polymerase (PPAR) cleavage [24].
Phosphatidyl-inositol-3-kinase (PI3K)/protein kinase B (AKT and the extracellular regulated
kinases/mitogen-activated protein kinase (ERKs/MAPK)) are the most relevant signaling pathways
involved in cell proliferation and survival regulation [6,7]. As mentioned above, PB2 (10 µM) and
a cocoa polyphenolic extract (10 µg/mL) protected colonic Caco-2 cells against acrylamide-induced
cytotoxicity by avoiding the increase in the levels of p-JNK induced by the toxic, whereas ERK seemed
to play an indirect protective role through the promotion of cell proliferation and survival signaling [20].
In the case of Caco-2 stressed with t-BOOH, PB2 (10 µM) also prevented cell damage by upregulating
GSTP1 through the activation of ERK and p38 and Nrf2 translocation [23]. Similarly, preincubation
of Caco-2 cells with hexameric procyanidins (10 µM, 30 min) averted oncogenic events initiated
by deoxycholic acid through the interaction with cell membranes and prevented the activation of
AKT, ERK and p38, as well as the transcription factor activator protein-1 (AP-1) [24]. Interestingly,
PB2 (20–50 µM, 24 h) promoted cell growth in SW480 cells by enhancing p-AKT and p-ERK levels,
although these proteins were unaffected under the same experimental conditions in Caco-2 cells [30].
EC (10–50 µM, 24 h) did not evoke any effect on Caco-2 and SW480 cell survival-proliferation
pathways [30]. This different response, ranging from no effect of any of the flavanols on Caco-2
cells to a survival/proliferative effect of PB2 on the SW480 cell line, depends on the distinct chemical
structure of the compound and the different degree of colon cancer cell differentiation [30]. Moreover,
it has been suggested that the capability of procyanidins to interact with the cell membrane and to
prevent cell membrane-associated events can in part explain their effects [24].
3. Chemopreventive Effects in Animal Models
Colon cancer prevention by cocoa and its major components can also be studied in animal
models of genetic and chemically-induced colon cancer. Although colonic cell culture models have
clearly demonstrated the antioxidant and chemopreventive abilities of cocoa and its flavonoids, only
experimental models for colorectal cancer could offer the opportunity to assess the contribution
of this natural dietary compound to the potential prevention of colon cancer. In this regard,
carcinogen-induced rodent models have been shown to mimic many features of human non-familial
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colorectal cancer (non-genetic based) [35], which is the most common type of colon cancer and which
occurs sporadically. Thus, induction of colon tumors could be achieved by the administration of
carcinogens, such as nitrosamines, heterocyclic amines, aromatic amines, 1,2-dimethylhydrazine and
azoxymethane (AOM). Among these, the AOM model has been extensively used to examine the
chemopreventive effect of numerous compounds on colon cancer [36]. Administration of AOM to
rodents induces the development of the ACF colonic preneoplastic lesions that may progress into
cancer with time [1]. Indeed, ACF represent the earliest identifiable intermediate precancerous lesions
during colon carcinogenesis in both laboratory animals and humans [37].
The potentially important role of cocoa and their phenolic compounds for colon cancer prevention
was first proven by Weyant and coworkers [38]. In this work, the authors demonstrated that the cocoa
flavanol catechin added to a diet (0.1 and 1%, which has been estimated by the authors to correspond
to a daily dose of 8 mg/kg (+)-catechin in humans, that is 480 mg for a 60-kg human that might be
obtained from approximately 25 g cocoa) reduced the formation of intestinal tumors by 75% and 71%,
respectively, in a genetic mice model of multiple intestinal neoplasia that spontaneously develops
multiple intestinal tumors. Further mechanistic studies related this effect to (+)-catechin-induced
changes in integrin-mediated intestinal cell-survival signaling, involving structural alteration of the
actin cytoskeleton and decreased focal adhesion kinase (FAK) tyrosine phosphorylation. All of these
suggested that (+)-catechin could prevent the progression of initiated enterocytes to the adenoma
stage, as FAK has been implicated in the regulation of cell migration, one of the earliest changes in
adenoma development [39].
In another study, male Wistar rats were fed with a cocoa-enriched diet (12%, which according
to the body surface area normalization method [40] would correspond to a daily dose of 78 g of
cocoa, containing 1560 mg of polyphenols, for a 60-kg human ) for eight weeks starting two weeks
before the AOM administration (20 mg/kg bw). As estimated, all rats injected with AOM developed
aberrant crypts (100% incidence) [41]. Nevertheless, the cocoa-rich diet diminished the AOM-induced
ACF formation and especially those ACF with larger number of crypts (ě4 crypts), which exhibit
a higher tendency to progress into malignancy. Therefore, a cocoa-supplemented diet was able
to abolish the early phase of chemically-induced colon carcinogenesis. This inhibitory effect of
cocoa on AOM-induced preneoplastic lesions was related to its anti-oxidative and anti-inflammatory
properties. Thus, cocoa circumvented the oxidative stress induced by AOM, as it recovered to
control levels the reduced content of GSH and the activities of GPx, GR and GST induced by
the toxic. Consequently, the cocoa-enriched diet avoided the subsequent enhancement in the
phosphorylated levels of AKT and ERK provoked by AOM, as well as the decrease in the values
of cyclin D1 and cell proliferation, measured as proliferating cell nuclear antigen levels (PCNA).
Cocoa flavanols also repressed intestinal inflammation induced by AOM by inhibiting the NF-κB
signaling and downregulating pro-inflammatory COX-2 and iNOS expression [41]. Furthermore, cocoa
supplementation upregulated Bax and downregulated Bcl-xL levels in the colon tissue of AOM-treated
rats, suggesting that cocoa was also able to induce apoptosis as another complementary mechanism of
chemoprevention during the progression of carcinogenesis [41]. In the same rat model of AOM-induced
colon cancer, a diet including dark chocolate has been reported to reduce cell proliferation and some
gene expression involving inflammation (COX-2 and p-65-NF-kB), resulting in a lower number of early
preneoplastic lesions [42].
To conclude with the animal experimentation, it has been very recently observed that dietary cocoa
(5% and 10%, which according to the body surface area normalization method would approximately
correspond to a daily dose of 32.5–65 g of cocoa, containing 650–1300 mg of polyphenols, for a
60-kg human) inhibits colitis-associated cancer in a mouse model of AOM/dextran sulfate sodium
(DSS)-induced chronic inflammation by preserving the redox status of the animals and limiting cell
proliferation [43]. Thus, cocoa ingestion for 62 days highly reduced lipid oxidation and prevented the
decrease in the activities/levels of antioxidant defenses (GSH, SOD, CAT, GPx and GR) induced by
AOM/DSS administration. Moreover, cocoa-rich diets effectively decreased the expression of iNOS
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and COX-2 and activated the Nrf2/Keap1 pathway, as well as its downstream targets, such as NQO1
and UDP-GT [43]. In the same experimental conditions, a cocoa-enriched diet was also able to suppress
the IL-6/STAT3 pathway and to induce apoptosis, as increased levels of Bax and caspase-3 together
with diminished Bcl-xl values were observed in cocoa-fed mice [44].
4. Evidence of Chemopreventive Effects in Humans
Even though cell culture and animal studies have indicated a promising cancer-preventive
efficiency, chemopreventive properties of cocoa polyphenols in patients remain to be clarified.
Epidemiologic studies of cocoa intake and colon cancer risk are few, and those assessing mortality
by cancer provide only weak support for a benefit of cocoa. Consequently, confirmation of colon
cancer-preventive efficacy in humans requires large and long-lasting controlled clinical trials.
4.1. Epidemiologic Studies
In support of the anti-colon cancer effect of cocoa is the case of the Kuna tribe living in the San Blas
district of Panama. Kuna drink a flavanol-rich cocoa as their main beverage, providing more than
900 mg/day, and, thus, probably have the most flavonoid-rich diet of any population [45]. When
cause-specific death rates from year 2000–2004 were compared in mainland Panama and the San Blas
islands where Kuna live by examining death certificates, the rate of cardiovascular disease and cancer
among island-dwelling Kuna was much lower than in mainland Panama. This comparatively lower
risk among Kuna might reflect a very high flavanol intake [45].
Another prominent case in support of the cancer-preventive effect of cocoa in humans is the
data from the Iowa Women’s Study, which provided evidence of an inverse relation between catechin
consumption and colorectal cancer incidence in post-menopausal women [46]. In the same line,
Rossi et al. [47] have shown that high dietary proanthocyanidin intake (not necessarily from cocoa) is
associated with a reduced risk of colorectal cancer, particularly cancer of the rectum. Nevertheless,
some human studies have failed to show a beneficial impact of cocoa intake in the rate of cancer
appearance. In this line, another study did not show a significant correlation between a high chocolate
dietary pattern and any stage of colorectal disease, ranging from polyps, to adenomas and colorectal
cancer [48]. In addition, an adenoma study performed in North Carolina also failed to detect a
significant association between chocolate consumption and lower prevalence of adenomatous polyps
and colorectal cancer [49]. This lack of correlation between chocolate intake and colon cancer could
be related to the intake of chocolates with a low amount of flavanols, i.e., with a small percentage of
cocoa, as the case of milk chocolate, and/or to a problem related to the power because of the small
sample size of the group [48].
Finally, there are a number of human studies that have shown a negative effect of cocoa intake on
overall cancer incidence and, in particular, on colon cancer. In a French case-control study, chocolate
was identified as a risk factor for colorectal cancer [50]. In this regard, it should be highlighted that
the high intake of refined carbohydrates and sugar, which is present in the chocolate, especially in
those with a low amount of cocoa, has been associated with colon cancer via their effect on insulin and
IGF-I [48]. In any case, the global association at least may serve to stimulate further epidemiological
and experimental studies.
4.2. Intervention Studies
At present, there are no human intervention studies aiming to show an association between cocoa
intake and colon cancer prevention, but a few human intervention trials show that cocoa positively
regulates intermediary factors in cancer progression [51].
Recently, different studies have focused on the modulation of antioxidant and anti-inflammatory
status by consumption of cocoa products. Spadafranca and co-workers [52] have reported that
dark chocolate consumption significantly improved DNA resistance to oxidative stress. In this trial,
healthy subjects were assigned to a daily intake of 45 g of dark chocolate or white chocolate (lacking
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flavonoids) for 14 days, and it has been shown that the oxidative damage to mononuclear blood
cells DNA was diminished in the group consuming dark chocolate after 2 h of ingestion, while the
effect disappeared after 22 h. The anti-inflammatory effect of cocoa flavanols has been reinforced
by in vitro and ex vivo studies, although these effects have not always been replicated in vivo [53].
Consequently, cocoa consumption reduced NF-κB activation in peripheral blood mononuclear cells
in healthy voluntaries [54], but biomarkers of inflammation, such as IL-6, were unaltered in patients
at high risk of cardiovascular disease consuming cocoa powder [55]. Although the results from the
limited epidemiological and human trials that are available are not conclusive, cocoa has consistently
demonstrated an ability to increase serum antioxidant status and, therefore, to theoretically reduce
cancer risk.
5. Conclusions
This review reports the potential chemopreventive actions of cocoa and its main flavanols against
colon cancer (Figure 2). In this line, their potential cellular molecular mechanisms of action include
the regulation of different antioxidant defenses and numerous key proteins of signal transduction
pathways related to inflammation, cell proliferation, differentiation and apoptosis. These actions could
contribute to preserve a balanced redox status and to prevent the initiation and progression of an
uncontrolled cell growth, as well as to avoid a pro-inflammatory environment. In addition, animal
studies have proven that cocoa and its main flavanols would prevent and/or slow down the initiation
promotion of colon cancer. However, amounts administrated are probably higher than what a person
should normally consume and, despite these doses could be achievable through supplementation,
more moderate quantities of cocoa would be desirable. Importantly, human intervention studies
have reported some favorable changes in biomarkers for antioxidant status. Therefore, it could be
suggested that daily consumption of small amounts of flavanols and procyanidins from cocoa or
chocolate, together with an ordinary dietary intake of flavonoids, would constitute a natural approach
to potentially prevent colon cancer with minimal toxicity. Nevertheless, cocoa and its derivative
products merit further investigations, since the molecular mechanisms of action are not completely
elucidated. Additionally, extensive well-controlled and well-designed human epidemiological and
intervention studies are needed to fully assess the potential of cocoa in terms of optimal dose, route of
administration, cancer targets and preventive activities.
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